Spyre Therapeutics Dividendo
Dividendo criteri di controllo 0/6
Spyre Therapeutics does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
-5.2%
Rendimento del riacquisto
Rendimento totale per gli azionisti | -5.2% |
Rendimento futuro dei dividendi | n/a |
Crescita dei dividendi | n/a |
Prossima data di pagamento dei dividendi | n/a |
Data di stacco del dividendo | n/a |
Dividendo per azione | n/a |
Rapporto di remunerazione | n/a |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Oct 01Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if SYRE's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if SYRE's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
Spyre Therapeutics Rendimento dei dividendi rispetto al mercato |
---|
Segmento | Rendimento dei dividendi |
---|---|
Azienda (SYRE) | n/a |
Fondo del 25% del mercato (US) | 1.5% |
Top 25% del mercato (US) | 4.5% |
Media del settore (Biotechs) | 2.2% |
Analista previsionale (SYRE) (fino a 3 anni) | n/a |
Dividendo notevole: Unable to evaluate SYRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate SYRE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate SYRE's payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as SYRE has not reported any payouts.